CLS 2210
benzenesulfonate derivative which cleans cardiac lymph vessels better tha hyaluronidase; thereby reduces the size of myocardial infarcts after coronary occlusion
Networked: 9
relevant articles (0 outcomes,
6 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Myocardial Infarction
|
2. | Coronary Occlusion
07/01/1985
- " The present experimental data indicate that intravenous CLS 2210 may have a definite role in the management of acute coronary occlusion. " 01/01/1992
- " This study, in rats, was designed to determine whether CLS 2210 would reduce mortality and infarct size after coronary occlusion. " 03/01/1986
- " To examine the role of cardiac lymphatic drainage in myocardial infarction, we quantified the effect of a lymphogogue, CLS 2210, on the number and appearance of myocardial lymphatics as well as the electrocardiogram following coronary occlusion in the dog. " 08/01/1990
- " The effects on the evolution of canine myocardial infarction (MI) of the lymphagogues hyaluronidase (hyaluronate glucanohydrolase) (known to reduce the size of MIs) and calcium dobesilate (calcium, 2,5-dihydroxybenzenesulfonate, CLS 2210) were compared in a coded, placebo-controlled study in 48 dogs, during the first 24 h after coronary occlusion. "
|
3. | Necrosis
|
4. | Infarction (Infarctions)
08/01/1991
- " For each infarction site, a statistically significant fall was reached earlier in the CLS 2210 group. " 01/01/1992
- " In a second series, the animals were randomized to receive as initial dose a bolus of either 50 mg/kg of CLS 2210 by intravenous infusion or placebo followed by 25 mg/kg/h of the same drug or placebo over 24 h: mortality and infarct size were assessed after 24 h. " 01/01/1992
- " This study, in rats, was designed to determine whether CLS 2210 would reduce mortality and infarct size after coronary occlusion. " 08/01/1991
- " To assess the effect of CLS 2210 (a new formulation of calcium dobesilate) on the evolution of acute myocardial infarction, 100 patients presenting their first infarct were distributed, according to their sequential admissions to the hospital, into CLS 2210-treated group (50 patients) or a comparison group (50 patients not receiving CLS 2210). " 01/01/1990
- " To determine the effect of calcium dobesilate (CLS 2210) on biochemical markers of acute myocardial infarction, and thereby assess its action in limiting myocardial necrosis, this compound was administered intravenously by a randomized, double-blind technique to 23 of 41 patients suffering their first infarction. "
|
5. | Diabetic Retinopathy (Retinopathy, Diabetic)
|
|
Related Drugs and Biologics
Related Therapies and Procedures